ORGO insider trading
NasdaqCM HealthcareOrganogenesis Holdings Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Company website: organogenesis.com
ORGO insider activity at a glance
FilingIQ has scored 497 insider transactions for ORGO since Dec 10, 2018. The most recent filing in our index is dated Mar 9, 2026.
Across the full history, 76 open-market purchases
and 83 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ORGO insider trades is 51.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ORGO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ORGO?
- FilingIQ tracks 497 Form 4 insider transactions for ORGO (Organogenesis Holdings Inc.), covering filings from Dec 10, 2018 onwards. 79 of those were filed in the last 90 days.
- Are ORGO insiders net buyers or net sellers?
- Across the full Form 4 history for ORGO, 76 transactions (15%) were open-market purchases and 83 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ORGO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ORGO in?
- Organogenesis Holdings Inc. (ORGO) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $487.34M.
Methodology & sources
Every ORGO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.